MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux
27 Januar 2023 - 06:00PM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT:
MAAT – the “Company”), a French clinical-stage biotech and a
pioneer in the development of Microbiome Ecosystem TherapiesTM
(MET) dedicated to improving survival outcomes for patients with
cancer, today announces the initiation of coverage of its stock
by Kepler Cheuvreux.
With a research report named “The Microbiome revolution”, Kepler
Cheuvreux today initiates coverage of MaaT Pharma with a Buy
recommendation.
This new coverage strengthens the visibility of MaaT Pharma’s
share among French and international institutional investors and is
in addition to those already carried out by the brokerage firms KBC
Securities, Kempen and Portzamparc/Groupe BNP Paribas.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, supports the development and expansion of its
pipeline by determining novel disease targets, evaluating drug
candidates, and identifying biomarkers for microbiome-related
conditions.
The company’s Microbiome Ecosystem Therapies are produced
through a standardized cGMP manufacturing and quality control
process to safely deliver the full diversity of the microbiome, in
liquid and oral formulations. MaaT Pharma benefits from the
commitment of world-leading scientists and established
relationships with regulators to support the integration of the use
of microbiome therapies in clinical practice.
MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230127005247/en/
MaaT Pharma – Investor Relations Hervé AFFAGARD
Co-Founder and CEO Siân CROUZET, COO/ CFO +33 4 28 29 14 00
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications – Corporate and Medical
Communications Gretchen SCHWEITZER or Charlotte SPITZ +49 171
351 27 33 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Feb 2023 bis Mär 2023
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Mär 2022 bis Mär 2023
